vTv Therapeutics Inc. (VTVT)
NASDAQ: VTVT · Real-Time Price · USD
20.90
+0.06 (0.29%)
At close: Oct 24, 2025, 4:00 PM EDT
20.70
-0.20 (-0.96%)
After-hours: Oct 24, 2025, 4:10 PM EDT
vTv Therapeutics Revenue
vTv Therapeutics had revenue of $17.00K in the twelve months ending June 30, 2025, down -98.30% year-over-year. In the year 2024, vTv Therapeutics had annual revenue of $1.02M.
Revenue (ttm)
$17.00K
Revenue Growth
-98.30%
P/S Ratio
8,808.92
Revenue / Employee
$739
Employees
23
Market Cap
149.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.02M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 2.02M | -1.99M | -49.61% |
| Dec 31, 2021 | 4.01M | -2.41M | -37.56% |
| Dec 31, 2020 | 6.41M | 3.65M | 132.05% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
VTVT News
- 17 days ago - vTv Therapeutics Announces New Appointments to its Scientific Advisory Board - GlobeNewsWire
- 5 weeks ago - vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting - GlobeNewsWire
- 7 weeks ago - UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 7 weeks ago - vTv Therapeutics to Participate in Upcoming September Investor Conferences - GlobeNewsWire
- 7 weeks ago - vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund - GlobeNewsWire
- 2 months ago - vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin - GlobeNewsWire
- 2 months ago - vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes - GlobeNewsWire